Skip to main content
Erschienen in: Journal of Cardiothoracic Surgery 1/2024

Open Access 01.12.2024 | Research

Double lung transplantation is better than single lung transplantation for end-stage chronic obstructive pulmonary disease: a meta-analysis

verfasst von: Yu-Chi Fang, Wen-Hsin Cheng, Hung-I Lu, Yi-Shi Wang, Kai-Hao Chuang, Hsing-Hua Lai, Yu Chen, Li-Chun Chen, Meng-Yun Tsai, Yu-Ping Chang, Kuo-Tung Huang, Chien-Ming Lo

Erschienen in: Journal of Cardiothoracic Surgery | Ausgabe 1/2024

Abstract

Background

Lung transplantation is one of the most common treatment options for patients with end-stage chronic obstructive pulmonary disease. However, the choice between single and double lung transplantation for these patients remains a matter of debate. Therefore, we performed a systematic search of medical databases for studies on single lung transplantation, double lung transplantation, and chronic obstructive pulmonary disease.

Methods

The rate ratio and hazard ratio of survival were analyzed. The meta-analysis included 15 case–control and retrospective registry studies.

Results

The rate ratios of the 3-year survival (0.937 and P = 0.041) and 5-year survival (0.775 and P = 0.000) were lower for single lung transplantation than for double lung transplantation. However, the hazard ratio did not differ significantly between the two.

Conclusions

Double lung transplantation was found to provide better benefits than single lung transplantation in terms of the long-term survival in patients with chronic obstructive pulmonary disease.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s13019-024-02654-6.
Yu-Chi Fang and Wen-Hsin Cheng contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
COPD
Chronic obstructive pulmonary disease
DLT
Double lung transplantation
SLT
Single lung transplantation

Background

Chronic obstructive pulmonary disease (COPD) is the most common indication for lung transplantation worldwide 1. Currently, lung transplantation is the final treatment strategy for patients with end-stage COPD. The points in favor of single lung transplantation (SLT) and double lung transplantation (DLT) are equivocal. However, researchers of some case–control series have reported better outcomes in patients who underwent DLT than in those who underwent SLT [1]; in their experience, SLT leads to a high rate of primary graft dysfunction. Conversely, a large retrospective registry analysis revealed equal outcomes between SLT and DLT [2]. We reviewed relevant published literature and noted two different opinions regarding SLT and BLT: most studies have indicated that DLT is better for survival than SLT, but others have provided data indicating equal outcomes between the two.
Therefore, we reviewed the existing literature on the subject and performed a meta-analysis of all included studies to determine whether SLT or DLT yielded better survival outcomes.

Methods

Search strategy and inclusion criteria

We searched the PubMed, Medline, and Scopus databases using one or more of the following keywords: “chronic obstructive pulmonary disease” and “single lung transplantation or double lung transplantation.” A total of 416 results were identified in the search. We excluded articles on animal studies; articles written in a language other than English; articles that were case reports, reviews, letters, and editorial comments; articles published before 2000; and articles on studies with less than 50 patients.
The primary inclusion criteria were that the study must compare two treatment arms, (i.e., SLT and DLT) and that all the included patients should have undergone lung transplantation for end-stage lung disease.

Data extraction and quality assessment

Two reviewers read all the included literature critically and extracted the relevant data, including the first author, year of publication, number of treatment arms, and survival results. The quality of the included studies was assessed by all authors using the Newcastle–Ottawa Scale, which comprises three parts for a case–control study or cohort study: “SELECTION” (four items), “COMPARABILITY” (one item), and “EXPOSURE” (three items). Disagreements between the two reviewers were resolved through discussions with the other authors, including the corresponding author.

Data synthesis and analysis

Patient survival was the primary outcome in this study. We used rate ratios to compare SLT and DLT. Some of the included studies used multiple variance analyses and presented data with hazard ratios; we also used these to compare SLT and DLT. A random effects model was used to pool individual rate ratios and hazard ratios. Heterogeneity was determined using I2 tests; I2 values of > 50% were considered indicative of obvious heterogeneity. Potential publication bias was determined using the Egger’s test and Funnel plots. Statistical significance was defined as P < 0.05. All statistical analyses were performed using the Comprehensive Meta-Analysis software, version 3 (Biostat, Englewood, NJ, USA).

Results

Study search and characteristics of the included patients

Overall, 416 records were identified through database searching. Two reviewers read the titles, abstracts, and keywords of these records, and selected 32 studies based on the inclusion and exclusion criteria (Fig. 1). These mostly comprised case–control studies and database analyses.
Seventeen of these were further excluded for the following reasons: patients with COPD were not separated from all lung transplant recipients [310]; survival data were not analyzed [1113]; problems were noted with the statistical analyses, i.e., hazard ratios did not fit the 95% confidence intervals [14, 15]; SLT and DLT were not compared [16, 17]; a simulated model was used to compare the effects of SLT and DLT for COPD on waitlist outcomes, but long-term survival data were not reported [18]; and the OPTN/UNOS database was analyzed, but detailed survival data were not reported [19].
Finally, 15 studies remained for data analysis; most comprised retrospective case–control studies [1, 2, 2032]. Some of these were single-center, retrospective case–control studies [1, 21, 23, 24, 28, 29]; the others were database cohort analyses [2, 20, 22, 2527, 3032]. The data extracted from all the included studies are provided in Table 1. We used the Newcastle–Ottawa Scale to appraise all the studies; the results are provided in Table 2.
Table 1
Patient characteristics, study methodology, and quality assessment of included trial
Author, year
Patients’ Diagnosis
Surgery
Study Design
Enrolled sample number
Mean age, years
Outcome measurement
Quality assessment
Pochettino et al., 2000 [1]
COPD
Lung Transplant
Retrospective Case–control
DLT: 46
SLT: 84
DLT: 51.1 ± 1.2
SLT: 56.2 ± 0.7
Functional assessment, overall survival, and survival following onset of BOS
7
Meyer et al., 2001 [20]
Emphysema/COPD
Lung Transplant
Retrospective cohort (ISHLT/UNOS database)
DLT: 425
SLT: 1835
DLT: 50.5 ± 7.1
SLT: 54.8 ± 6.3
Mortality and Morbidity analysis
8
Cassivi et al., 2002 [21]
COPD/AATD
Lung Transplant
Retrospective Case–control
DLT: 112
SLT: 228
Total: 55.2 ± 6.4
Survival, Posttransplant functional result, morbidity
7
Burton et al., 2005 [22]
All suitable for lung transplant cases
Lung Transplant
Retrospective Case–control
DLT: 228
SLT: 112
(Median)
DLT: 45
SLT: 56
Survival rates for the center as a whole and compared survival rates between different sub-groups of patients
7
Hadjiliadis et al., 2006 [24]
COPD/AATD
Lung Transplant
Retrospective cohort (2 centers)
DLT: 103
SLT: 118
DLT: 53.0 ± 7.8
SLT: 55.3 ± 8.0
The effect of transplant on the development of BOS, survival, and survival after BOS in patients with COPD and alpha-1-antitrypsin deficiency
7
Gunes et al., 2006 [23]
COPD
Lung Transplant
Retrospective Case–control
DLT: 99
SLT: 66
Total: 50 ± 6
Outcomes of lung transplant for COPD (A-1 & cigarette smoking)
7
Stavem et al., 2006 [25]
All suitable for lung transplant cases
Lung Transplant
Retrospective Case–control
DLT: 37
SLT: 49
Total: 49.6 ± 8.9
The impact of diagnosis, SLT vs BLT, and the timing of transplant on the survival of patients placed on the waiting list for lung transplantation in Norway from 1990 to 2003
7
Nwakanma et al., 2007 [26]
All suitable for lung transplant cases over 60 years old
Lung Transplant
Retrospective Cohort (UNOS)
DLT: 224
SLT: 863
(All Diagnosis)
DLT: 62.3 ± 2.1
SLT: 62.8 ± 2.5
The impact of procedure type on short- and mid-term survival in recipients 60 years of age or older for all disease types
7
Thabut et al., 2008 (Am J Respir Crit Care Med) [27]
COPD
Lung Transplant
Retrospective Cohort (UNOS)
Total: 5873
DLT: 27.8%
SLT: 72.2%
Total: 56.0 ± 7.1
Analyze data from the UNOS registry to
(1) determine the survival
(2) patients with COPD most likely to benefit from LT
(3) create an instrument for caregivers to compute the expected survival effect of LT for a given patient
7
Thabut et al., 2008 (Lancet) [2]
COPD
Lung Transplant
Retrospective Cohort (ISHLT)
DLT: 3525
SLT: 6358
DLT: 52.2 ± 7.8
SLT: 55.5 ± 6.8
Compare survival rates after bilateral and single lung transplantation for patients with COPD
8
Delgado et al., 2009 [28]
Pulmonary emphysema
Lung Transplant
Retrospective Case–control
DLT: 33
SLT: 29
Total: 53.89 ± 6.75
Propose single lung transplant as the first-choice treatment for patients with a diagnosis of emphysema
6
Bennett et al., 2015 [29]
COPD
Lung Transplant
Retrospective Case–control (Single-Center) and Cohort (UNOS)
DLT: 30
SLT: 206
(UNOS) DLT: 2848
DLT: 58.89 ± 4.54
SLT: 52.41 ± 5.02
(UNOS) DLT: 57.48 ± 7.47
Comparable 5-year survival among the single-center SLTx cohort and BLTx recipients at both the local and national levels
8
Schaffer et al., 2015 [30]
COPD/IPF
Lung Transplant
Retrospective Cohort (ISHLT)
DLT: 1875
SLT: 1299
DLT: 59.4 ± 6.4
SLT: 61.6 ± 5.5
Reviewed UNOS data to summarize outcomes of IPF and COPD who underwent single- or double lung transplantation since the LAS was implemented
8
Gulack et al., 2018 [31]
COPD/AATD
Lung Transplant
Retrospective Cohort (UNOS)
DLT: 5688
SLT: 3881
(Median)
DLT: 57
SLT: 58
Hypothesized that patients with AATD have superior long-term survival following lung transplantation than patients with COPD
8
Crawford et al., 2019 [32]
COPD
Lung Transplant
Retrospective Cohort (UNOS)
DLT: 2196
SLT: 1358
DLT: 60 ± 6
SLT: 62 ± 5
Evaluate survivals in lung
transplant recipients with COPD among SLT and DLT cohorts
8
Abbreviations: AATD alpha-1-antitrypsin deficiency, DLT double lung transplant, SLT single lung transplant, COPD chronic obstructive pulmonary disease, IPF idiopathic pulmonary fibrosis, BOS bronchiolitis obliterans syndrome, UNOS United Network for Organ Sharing, ISHLT International Society for Heart and Lung Transplantation
Table 2
The detail of quality assessment of the included studies
Case–control Study
Author, year
Selection
Comparability
Exposure
Quality assessment
Is the case definition adequate?
Representativeness of the cases
Selection of Controls
Definition of Controls
Comparability of cases and controls on the basis of the design or analysis
Ascertainment of exposure
Same method of ascertainment for cases and controls
Non-response rate
 
Pochettino et al., 2000 [1]
*
*
 
*
**
*
*
 
7
Cassivi et al., 2002 [21]
*
*
 
*
**
*
*
 
7
Burton et al., 2005 [22]
*
*
 
*
**
*
*
 
7
Gunes et al., 2006 [23]
*
*
 
*
**
*
*
 
7
Stavem et al., 2006 [25]
*
*
 
*
**
*
*
 
7
Delgado et al., 2009 [28]
*
*
 
*
*
*
*
 
6
 
Selection
Comparability
Exposure
Quality assessment
Representativeness of the exposed cohort
Selection of the non-exposed cohort
Ascertainment of exposure
Demonstration that outcome of interest was not present at the start of study
Comparability of cohorts on the basis of the design or analysis
Assessment of outcome
Was follow-up long enough for outcomes to occur?
Adequacy of follow-up of cohorts
 
Meyer et al., 2001 [20]
*
*
 
*
**
*
*
*
8
Hadjiliadis et al., 2006 [24]
*
*
 
*
**
*
*
*
8
Nwakanma et al., 2007 [26]
*
*
 
*
**
*
*
 
7
Thabut et al., 2008 (Am J Respir Crit Care Med) [27]
*
*
 
*
**
*
*
 
7
Thabut et al., 2008 (Lancet) [2]
*
*
 
*
**
*
*
*
8
Bennett et al., 2015 [29]
*
*
 
*
**
*
*
*
8
Schaffer et al., 2015 [30]
*
*
 
*
**
*
*
*
8
Gulack et al., 2018 [31]
*
*
 
*
**
*
*
*
8

Pooled rate ratio and hazard ratio of survival

We analyzed the survival rate and compared the same between the SLT and DLT groups in each study. We also included the 1-year, 3-year, and 5-year survival data in the analysis. In some studies, results were obtained using multiple variance analyses and hazard ratios; we performed a separate analysis for these studies [2, 25, 27, 30].
The pooled rate ratios were 0.98 (P = 0.646; Fig. 2), 0.937 (P = 0.041; Fig. 3), and 0.775 (P = 0.000; Fig. 4) for the 1-year, 3-year, and 5-year survival, respectively.
The pooled hazard ratio of survival was 0.857 (P = 0.388; Fig. 5a). Thabut et al. analyzed the International Society for Heart and Lung Transplantation database and reported different data after propensity score matching [2]. We included their study, with two different results, in the analysis because the P values were not significant. The pooled hazard ratio was 0.956 (P = 0.755; Fig. 5b).
The Egger’s test did not reveal a significant publication bias in the following: 1) pooled rate ratio analyses of the 1-year (P = 0.154), 3-year (P = 0.097), and 5-year (P = 0.242) survival; 2) hazard ratio analysis (P = 0.711); and 3) hazard ratio analysis with Thabut et al.’s propensity score matching results (P = 0.188). The Funnel plots are presented in Figs. 6, 7, 8, 9a and b.

Discussion

Patients with end-stage COPD are often recommended to undergo lung transplantation, which is currently the most acceptable treatment method. However, the debate between SLT and DLT still exists [33]. Lung transplantation is a complex and difficult surgery, and procedure selection is known to affect patient survival [34].
Our analysis showed that the early survival outcomes were equal between SLT and DLT. However, DLT achieved a better mid-term and long-term survival than SLT. The pooled hazard ratio did not reveal a significant difference between the two.
Most of the case–control series revealed a better outcome for DLT [1, 21, 24, 28, 29]. However, analysis studies based on a large registry revealed equal outcomes for both methods [2, 30]. Besides, DLT could bring about an organ shortage and increase the risk of mortality in patients on the waiting list. This is the primary reason the current review did not recommend whether patients with end-stage COPD should receive SLT or DLT.
The retrospective database study by Thabut et al. is an important one; it majorly contributed to the present meta-analysis due to its large sample size. Thabut et al. used different statistical methods (including propensity score matching) in an attempt to reduce the effect of confounding factors. They achieved the same result with these methods. We chose to include their study because we thought that their data, obtained with multiple methods, would allow us to better compare SLT and DLT.
The choice between DLT and SLT remains debatable. Waiting list mortality is major concern during choosing the appropriate procedure. SLT can reduce the waiting times associated with organ shortage [29]. However, DLT has been proven to yield better survival and quality of life outcomes in some studies [1]. This conflict will affect the choice of procedure, especially when the patient’s age is taken into consideration. DLT could provide a better quality of life for larger lung volumes [1]. For younger recipients, this is an important factor to consider while discussing the treatment plans with the transplantation team.
Our study had several limitations. First, all the included studies were case–control studies or retrospective analyses of registry data. Thus, the evidence level was not high. Several additional factors affect patient survival, including the patient’s age, center where the surgery is conducted and the facilities available there, and the surgeon’s experience and expertise. Two of the included studies involved age-based analyses [2, 20]; however, the meta-analysis pooled their data and masked the effect of age.
Furthermore, we excluded studies published before 2000 because surgery techniques and critical care have undergone significant changes in the past 20 years. The aforementioned factors would have affected our results had we included studies published before 2000 in our meta-analysis. Accordingly, we further excluded case–control studies with less than 50 patients since such low-volume studies could also affect our results.
It is impossible to conduct a prospective randomized trial on this subject due to ethical considerations regarding patient treatment. However, a retrospective registry analysis across multiple countries and comparison of the obtained results may provide data beneficial for patients with end-stage COPD worldwide. The more retrospective studies published, the more data we can collect for a meta-analysis to determine the different factors related to the outcomes of the two transplantation procedures.

Conclusions

We determined that in patients with end-stage COPD, DLT results in a better 3-year and 5-year survival than SLT.

Acknowledgements

None.

Declarations

The authors are accountable for all aspects of the work to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This article used published accessible literature that did not contain deeply personal, sensitive, or confidential information of the participants. Therefore, institutional review board approval was not necessary.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Pochettino A, Kotloff RM, Rosengard BR, Arcasoy SM, Blumenthal NP, Kaiser LR, et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease: intermediate-term results. Ann Thorac Surg. 2000;70(6):1813–8; discussion 8-9.CrossRefPubMed Pochettino A, Kotloff RM, Rosengard BR, Arcasoy SM, Blumenthal NP, Kaiser LR, et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease: intermediate-term results. Ann Thorac Surg. 2000;70(6):1813–8; discussion 8-9.CrossRefPubMed
2.
Zurück zum Zitat Thabut G, Christie JD, Ravaud P, Castier Y, Brugière O, Fournier M, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet (London, England). 2008;371(9614):744–51.CrossRefPubMed Thabut G, Christie JD, Ravaud P, Castier Y, Brugière O, Fournier M, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet (London, England). 2008;371(9614):744–51.CrossRefPubMed
3.
Zurück zum Zitat Moffatt SD, Demers P, Robbins RC, Doyle R, Wienacker A, Henig N, et al. Lung transplantation: a decade of experience. J Heart Lung Transplant. 2005;24(2):145–51.CrossRefPubMed Moffatt SD, Demers P, Robbins RC, Doyle R, Wienacker A, Henig N, et al. Lung transplantation: a decade of experience. J Heart Lung Transplant. 2005;24(2):145–51.CrossRefPubMed
4.
Zurück zum Zitat Thacker J, Toyoda Y. Lung and heart-lung transplantation at University of Pittsburgh: 1982–2009. Clinical transplants. 2009:179–95. Thacker J, Toyoda Y. Lung and heart-lung transplantation at University of Pittsburgh: 1982–2009. Clinical transplants. 2009:179–95.
5.
Zurück zum Zitat Jesel L, Barraud J, Lim HS, Marzak H, Messas N, Hirschi S, et al. Early and late atrial arrhythmias after lung transplantation- incidence, predictive factors and impact on mortality. Circ J. 2017;81(5):660–7.CrossRefPubMed Jesel L, Barraud J, Lim HS, Marzak H, Messas N, Hirschi S, et al. Early and late atrial arrhythmias after lung transplantation- incidence, predictive factors and impact on mortality. Circ J. 2017;81(5):660–7.CrossRefPubMed
6.
Zurück zum Zitat Salamo O, Roghaee S, Schweitzer MD, Mantero A, Shafazand S, Campos M, et al. White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients. Sci Rep. 2018;8(1):6968.CrossRefPubMedPubMedCentral Salamo O, Roghaee S, Schweitzer MD, Mantero A, Shafazand S, Campos M, et al. White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients. Sci Rep. 2018;8(1):6968.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Schuba B, Scheklinski M, von Dossow V, Schneider C, Preissler G, Kneidinger N, et al. Five-year experience using the lung allocation score: the munich lung transplant group. Eur J CardioThorac Surg. 2018;54(2):328–33.CrossRefPubMed Schuba B, Scheklinski M, von Dossow V, Schneider C, Preissler G, Kneidinger N, et al. Five-year experience using the lung allocation score: the munich lung transplant group. Eur J CardioThorac Surg. 2018;54(2):328–33.CrossRefPubMed
8.
Zurück zum Zitat Van Raemdonck D, Keshavjee S, Levvey B, Cherikh WS, Snell G, Erasmus M, et al. Donation after circulatory death in lung transplantation-five-year follow-up from ISHLT Registry. J Heart Lung Transplant. 2019;38(12):1235–45.CrossRefPubMed Van Raemdonck D, Keshavjee S, Levvey B, Cherikh WS, Snell G, Erasmus M, et al. Donation after circulatory death in lung transplantation-five-year follow-up from ISHLT Registry. J Heart Lung Transplant. 2019;38(12):1235–45.CrossRefPubMed
9.
Zurück zum Zitat Blitzer D, Copeland H, Roe D, Hage C, Wang IW, Duncan M, et al. Long term survival after lung transplantation: A single center experience. J Card Surg. 2020;35(2):273–8.CrossRefPubMed Blitzer D, Copeland H, Roe D, Hage C, Wang IW, Duncan M, et al. Long term survival after lung transplantation: A single center experience. J Card Surg. 2020;35(2):273–8.CrossRefPubMed
10.
Zurück zum Zitat AworiHayanga JW, Aboagye JK, Shigemura N, Hayanga HK, Murphy E, Khaghani A, et al. Airway complications after lung transplantation: Contemporary survival and outcomes. J Heart Lung Transplant. 2016;35(10):1206–11.CrossRef AworiHayanga JW, Aboagye JK, Shigemura N, Hayanga HK, Murphy E, Khaghani A, et al. Airway complications after lung transplantation: Contemporary survival and outcomes. J Heart Lung Transplant. 2016;35(10):1206–11.CrossRef
11.
Zurück zum Zitat Paradela M, González D, Parente I, Fernández R, De La Torre MM, Delgado M, et al. Surgical risk factors associated with lung transplantation. Transpl Proc. 2009;41(6):2218–20.CrossRef Paradela M, González D, Parente I, Fernández R, De La Torre MM, Delgado M, et al. Surgical risk factors associated with lung transplantation. Transpl Proc. 2009;41(6):2218–20.CrossRef
12.
Zurück zum Zitat Shadmehr MB, Arab M, Pejhan S, Daneshvar A, Javaherzadeh N, Abbasi A, et al. Eight years of lung transplantation: experience of the National Research Institute of Tuberculosis and Lung Diseases. Transpl Proc. 2009;41(7):2887–9.CrossRef Shadmehr MB, Arab M, Pejhan S, Daneshvar A, Javaherzadeh N, Abbasi A, et al. Eight years of lung transplantation: experience of the National Research Institute of Tuberculosis and Lung Diseases. Transpl Proc. 2009;41(7):2887–9.CrossRef
13.
Zurück zum Zitat Oto T, Griffiths AP, Levvey BJ, Pilcher DV, Williams TJ, Snell GI. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg. 2006;132(1):140–7.CrossRefPubMed Oto T, Griffiths AP, Levvey BJ, Pilcher DV, Williams TJ, Snell GI. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg. 2006;132(1):140–7.CrossRefPubMed
14.
Zurück zum Zitat Wang Q, Rogers CA, Bonser RS, Banner NR, Demiris N, Sharples LD. Assessing the benefit of accepting a single lung offer now compared with waiting for a subsequent double lung offer. Transplantation. 2011;91(8):921–6.CrossRefPubMed Wang Q, Rogers CA, Bonser RS, Banner NR, Demiris N, Sharples LD. Assessing the benefit of accepting a single lung offer now compared with waiting for a subsequent double lung offer. Transplantation. 2011;91(8):921–6.CrossRefPubMed
15.
Zurück zum Zitat Anderson MR, Tabah A, RoyChoudhury A, Lederer DJ. Procedure preference and intention-to-treat outcomes after listing for lung transplantation among U.S. adults. A cohort study. Ann Am Thorac Soc. 2019;16(2):231–9.CrossRefPubMedPubMedCentral Anderson MR, Tabah A, RoyChoudhury A, Lederer DJ. Procedure preference and intention-to-treat outcomes after listing for lung transplantation among U.S. adults. A cohort study. Ann Am Thorac Soc. 2019;16(2):231–9.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat de Perrot M, Chaparro C, McRae K, Waddell TK, Hadjiliadis D, Singer LG, et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg. 2004;127(5):1493–501.CrossRefPubMed de Perrot M, Chaparro C, McRae K, Waddell TK, Hadjiliadis D, Singer LG, et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg. 2004;127(5):1493–501.CrossRefPubMed
17.
Zurück zum Zitat Latos M, Nęcki M, Pawlak D, Urlik M, Antończyk R, Ochman M, et al. Outcome of lung transplantation as a treatment of patients with chronic obstructive pulmonary disease: a single-center study. Transplant Proc. 2020;52(7):2118–22.CrossRefPubMed Latos M, Nęcki M, Pawlak D, Urlik M, Antończyk R, Ochman M, et al. Outcome of lung transplantation as a treatment of patients with chronic obstructive pulmonary disease: a single-center study. Transplant Proc. 2020;52(7):2118–22.CrossRefPubMed
18.
Zurück zum Zitat Munson JC, Christie JD, Halpern SD. The societal impact of single versus bilateral lung transplantation for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(11):1282–8.CrossRefPubMedPubMedCentral Munson JC, Christie JD, Halpern SD. The societal impact of single versus bilateral lung transplantation for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(11):1282–8.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Cai J. Double- and single-lung transplantation: an analysis of twenty years of OPTN/UNOS registry data. Clin Transpl. 2007:1–8. Cai J. Double- and single-lung transplantation: an analysis of twenty years of OPTN/UNOS registry data. Clin Transpl. 2007:1–8.
20.
Zurück zum Zitat Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence of recipient age on survival and secondary end-points. J Heart Lung Transplant. 2001;20(9):935–41.CrossRefPubMed Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence of recipient age on survival and secondary end-points. J Heart Lung Transplant. 2001;20(9):935–41.CrossRefPubMed
21.
Zurück zum Zitat Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, Lynch JP, et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg. 2002;74(5):1663–9; discussion 9-70.CrossRefPubMed Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, Lynch JP, et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg. 2002;74(5):1663–9; discussion 9-70.CrossRefPubMed
22.
Zurück zum Zitat Burton CM, Milman N, Carlsen J, Arendrup H, Eliasen K, Andersen CB, et al. The Copenhagen National Lung Transplant Group: survival after single lung, double lung, and heart-lung transplantation. J Heart Lung Transplant. 2005;24(11):1834–43.CrossRefPubMed Burton CM, Milman N, Carlsen J, Arendrup H, Eliasen K, Andersen CB, et al. The Copenhagen National Lung Transplant Group: survival after single lung, double lung, and heart-lung transplantation. J Heart Lung Transplant. 2005;24(11):1834–43.CrossRefPubMed
23.
Zurück zum Zitat Güneş A, Aboyoun CL, Morton JM, Plit M, Malouf MA, Glanville AR. Lung transplantation for chronic obstructive pulmonary disease at St Vincent’s Hospital. Intern Med J. 2006;36(1):5–11.CrossRefPubMed Güneş A, Aboyoun CL, Morton JM, Plit M, Malouf MA, Glanville AR. Lung transplantation for chronic obstructive pulmonary disease at St Vincent’s Hospital. Intern Med J. 2006;36(1):5–11.CrossRefPubMed
24.
Zurück zum Zitat Hadjiliadis D, Chaparro C, Gutierrez C, Steele MP, Singer LG, Davis RD, et al. Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease. Am J Transplant. 2006;6(1):183–9.CrossRefPubMed Hadjiliadis D, Chaparro C, Gutierrez C, Steele MP, Singer LG, Davis RD, et al. Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease. Am J Transplant. 2006;6(1):183–9.CrossRefPubMed
25.
Zurück zum Zitat Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. J Heart Lung Transplant. 2006;25(1):75–84.CrossRefPubMed Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. J Heart Lung Transplant. 2006;25(1):75–84.CrossRefPubMed
26.
Zurück zum Zitat Nwakanma LU, Simpkins CE, Williams JA, Chang DC, Borja MC, Conte JV, et al. Impact of bilateral versus single lung transplantation on survival in recipients 60 years of age and older: analysis of United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2007;133(2):541–7.CrossRefPubMed Nwakanma LU, Simpkins CE, Williams JA, Chang DC, Borja MC, Conte JV, et al. Impact of bilateral versus single lung transplantation on survival in recipients 60 years of age and older: analysis of United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2007;133(2):541–7.CrossRefPubMed
27.
Zurück zum Zitat Thabut G, Ravaud P, Christie JD, Castier Y, Fournier M, Mal H, et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(10):1156–63.CrossRefPubMed Thabut G, Ravaud P, Christie JD, Castier Y, Fournier M, Mal H, et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(10):1156–63.CrossRefPubMed
28.
Zurück zum Zitat Delgado M, Borro JM, De La Torre MM, Fernández R, González D, Paradela M, et al. Lung transplantation as the first choice in emphysema. Transpl Proc. 2009;41(6):2207–9.CrossRef Delgado M, Borro JM, De La Torre MM, Fernández R, González D, Paradela M, et al. Lung transplantation as the first choice in emphysema. Transpl Proc. 2009;41(6):2207–9.CrossRef
29.
Zurück zum Zitat Bennett DT, Zamora M, Reece TB, Mitchell JD, Cleveland JC Jr, Grover FL, et al. Continued utility of single-lung transplantation in select populations: chronic obstructive pulmonary disease. Ann Thorac Surg. 2015;100(2):437–42.CrossRefPubMed Bennett DT, Zamora M, Reece TB, Mitchell JD, Cleveland JC Jr, Grover FL, et al. Continued utility of single-lung transplantation in select populations: chronic obstructive pulmonary disease. Ann Thorac Surg. 2015;100(2):437–42.CrossRefPubMed
30.
Zurück zum Zitat Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313(9):936–48.CrossRefPubMed Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313(9):936–48.CrossRefPubMed
31.
Zurück zum Zitat Gulack BC, Mulvihill MS, Ganapathi AM, Speicher PJ, Chery G, Snyder LD, et al. Survival after lung transplantation in recipients with alpha-1-antitrypsin deficiency compared to other forms of chronic obstructive pulmonary disease: a national cohort study. Transpl Int. 2018;31(1):45–55.CrossRefPubMed Gulack BC, Mulvihill MS, Ganapathi AM, Speicher PJ, Chery G, Snyder LD, et al. Survival after lung transplantation in recipients with alpha-1-antitrypsin deficiency compared to other forms of chronic obstructive pulmonary disease: a national cohort study. Transpl Int. 2018;31(1):45–55.CrossRefPubMed
32.
Zurück zum Zitat Crawford TC, Lui C, Magruder JT, Ha JS, Higgins RS, Merlo CA, et al. Five-year mortality hazard is reduced in chronic obstructive pulmonary disease patients receiving double- versus single-lung transplants. J Surg Res. 2019;237:118–25.CrossRefPubMed Crawford TC, Lui C, Magruder JT, Ha JS, Higgins RS, Merlo CA, et al. Five-year mortality hazard is reduced in chronic obstructive pulmonary disease patients receiving double- versus single-lung transplants. J Surg Res. 2019;237:118–25.CrossRefPubMed
33.
Zurück zum Zitat Siddiqui FM, Diamond JM. Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions. Curr Opin Pulm Med. 2018;24(2):199–204.CrossRefPubMedPubMedCentral Siddiqui FM, Diamond JM. Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions. Curr Opin Pulm Med. 2018;24(2):199–204.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch K, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1047–59.CrossRefPubMed Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch K, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1047–59.CrossRefPubMed
Metadaten
Titel
Double lung transplantation is better than single lung transplantation for end-stage chronic obstructive pulmonary disease: a meta-analysis
verfasst von
Yu-Chi Fang
Wen-Hsin Cheng
Hung-I Lu
Yi-Shi Wang
Kai-Hao Chuang
Hsing-Hua Lai
Yu Chen
Li-Chun Chen
Meng-Yun Tsai
Yu-Ping Chang
Kuo-Tung Huang
Chien-Ming Lo
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
Journal of Cardiothoracic Surgery / Ausgabe 1/2024
Elektronische ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-024-02654-6

Weitere Artikel der Ausgabe 1/2024

Journal of Cardiothoracic Surgery 1/2024 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.